Logo
x

Search

Subscribe Now

Alopecia Areata

Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata

Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata

  • August 5, 2021
Concert's CTP-543 Receives the US FDA's Breakthrough Therapy Designation to Treat Alopecia Areata

Concert's CTP-543 Receives the US FDA's Breakthrough Therapy Designation to Treat Alopecia Areata

  • July 8, 2020
Eli Lilly and Incyte's Olumiant (baricitinib) Receives the US FDA's Breakthrough Therapy Designation for Alopecia Areata

Eli Lilly and Incyte's Olumiant (baricitinib) Receives the US FDA's Breakthrough Therapy Designation for Alopecia Areata

  • March 16, 2020
Sun Pharma to Acquire Concert Pharmaceuticals for ~$576M

    Sun Pharma to Acquire Concert Pharmaceuticals for ~$576M

    • January 20, 2023
    Pfizer Reports the US FDA and EMA

      Pfizer Reports the US FDA and EMA's Acceptance of NDA & MAA for Ritlecitinib to Treat Alopecia Areata in Patients Aged ≥12 Years

      • September 9, 2022
      Eli Lilly and Incyte’ Olumiant (baricitinib) Receives the US FDA’s Approval as First-In-Disease Systemic Treatment for Adults with Severe Alopecia Areata

        Eli Lilly and Incyte’ Olumiant (baricitinib) Receives the US FDA’s Approval as First-In-Disease Systemic Treatment for Adults with...

        • June 14, 2022
        Eli Lilly and Incyte Receive CHMP Positive Opinion of Olumiant (baricitinib) for the Treatment of Adults with Severe Alopecia Areata

          Eli Lilly and Incyte Receive CHMP Positive Opinion of Olumiant (baricitinib) for the Treatment of Adults with Severe Alopecia Area...

          • May 23, 2022
          Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata

            Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata

            • August 5, 2021
            Lilly and Incyte Report Results of Baricitinib in P-III BRAVE-AA1 Study for Severe Alopecia Areata

              Lilly and Incyte Report Results of Baricitinib in P-III BRAVE-AA1 Study for Severe Alopecia Areata

              • April 20, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.